Nalaganje...
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
Lung cancer is the leading cause of cancer death in the United States. The vast majority of patients are diagnosed with metastatic disease with a 5-year survival rate of less than 5%. After first-line chemotherapy or biomarker-matched targeted therapy, only suitable for a small group of patients, fu...
Shranjeno v:
| izdano v: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066544/ https://ncbi.nlm.nih.gov/pubmed/27800034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016661164 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|